Endocyte, Inc is a biopharmaceutical company that has developed a targeted small molecule drug conjugates ( SMDC).
This agent helps to improve the way prostate cancer is diagnosed and treated. This company tends to apply for an investigational new drug before the end of the year.
This is based on the fact that its imaging agent has achieved key success in a recent study. More details on what this company is up to are highlighted below:
Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced the achievement of key objectives in a Phase 0 study of EC0652, a diagnostic imaging agent targeting prostate specific membrane antigen (PSMA), a protein expressed on cancer cells originating from the prostate as well as on tumor neovasculature.
Based on the observed safety of the agent and its specificity for binding to diseased cells, Endocyte is advancing the development of both the diagnostic imaging agent, EC0652, and the corresponding therapeutic agent, EC1069, a proprietary PSMA-targeted SMDC linked with the potent anti-cancer drug tubulysin. Endocyte expects to file an Investigational New Drug (IND) application for EC1069 by the end of 2013.
The new prostate cancer imaging agent EC0652, also termed DUPA-99mTc, is a conjugate of a high affinity PSMA-targeting ligand, 2-[3-(1, 3-dicarboxy propyl)-ureido] pentanedioic acid (DUPA) to technetium 99m (99mTc).
The discovery process utilized a unique structure-based drug design approach to synthesize the ideal targeting ligand for binding to PSMA. The corresponding SMDC, EC1069, utilizes the same targeting ligand.
“DUPA has demonstrated excellent localization to prostate cancer regionally and at distant sites,” said Thomas A. Gardner, M.D., professor of urology at Indiana University Health. “These results encourage us to investigate this novel agent for both imaging and therapeutic applications for prostate cancer.”
“We have generated a number of unique development methods to optimize the design of our targeting ligands and maximize specificity, and our approach is yielding superior results with new ligands of much higher specificity than other methods,” commented Philip Low, Ph.D., Endocyte’s chief science officer. “We are also using this approach to develop ligands to target several other diseases as we continue to expand our SMDC platform.”
The imaging study is being led by the Purdue University Center for Cancer Research and performed at the Department of Urology at the Indiana University School of Medicine. Detailed results of this study are anticipated to be presented at an upcoming medical conference.
Endocyte is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. Endocyte uses its proprietary technology to create novel SMDCs and companion imaging diagnostics for personalized targeted therapies. The company’s SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells.
This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently, and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging diagnostics are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment.
For additional information, please visit Endocyte’s website at www.endocyte.com. Source.
Conclusively, Endocyte Inc may particularly not ring bell in the medical field but its achievements with the SMDCs are remarkable. Imaging agents for prostate cancer diagnosis and treatments are significant study or research interest.
As mentioned above, the company’s website will provide readers with updates on the success achieved with the EC0652 diagnostic imaging agent which targets prostate specific membrane antigen (PSMA).
If you have prolonged psychological stress, you are more likely to have an unfavorable outcome with prostate cancer treatment. This observation has been noted by experts in the wake of a recent animal study that reveal behavioral stress promotes tumor progression.
Denise Reynolds RD once again highlighted this point in an article posted January 31, 2013 in eMaxHealth. Reynolds states that:
Psychological stress describes how people feel emotionally when they are under pressure. But the effects do not stop in the brain.
The body responds to this pressure by releasing hormones such as epinephrine and norepinephrine that increase blood pressure, speed heart rate and raise blood sugar levels.
There is also evidence that stress during cancer can shorten the length of telomeres, the ends of chromosomes that deteriorate with aging which is linked to a shorter lifespan.”
More so, this observation can readily be linked with the findings of researchers at Wake Forest University that revealed that stressed mice exhibited reduced response to anti cancer drug unlike unstressed mice.
More so, The authors note that men with prostate cancer seem to be affected by their diagnosis more than other cancer patients, exhibiting higher levels of anxiety. Levels of PSA also have been observed to increase in patients under behavioral stress.
Drugs that block the effects of adrenaline, such as beta-blockers (used for the treatment of high blood pressure), appeared to reduce the risk of prostate cancer by 18% indicating that this medication could be useful to increase the effectiveness of anti-cancer therapies.
Emotional and social support can also help cancer patients cope with psychological stress. Approaches can include relaxation training, meditation, counseling, support groups, anti-depression/anti-anxiety medications, or exercise, including mind-body techniques such as yoga or tai chi.
Conclusively, from the previous paragraphs, the effects of stress in prostate cancer cannot be undermined. The suggested emotional and social support can be applied to help ease stress for men diagnosed with prostate cancer.
It is very possible that when treatments are applied under a relaxed condition there is going to be better response and improved quality of life. Read more about this in the post made by Denise Reynolds RD.
Early-stage or localized prostate cancer can be treated with surgery or radiation.
In the longest follow-up study of men that underwent surgery and radiation as treatment options for their condition, sexual, bladder and bowel troubles have been noticed in these men.
The study which reveals the side effects is published fifteen years after the treatments were administered. Details of this new study and most importantly how the treatments have impacted sexual lives of men have been highlighted below:
A new study shows how important it is for men to carefully consider treatments for early-stage prostate cancer. Fifteen years after surgery or radiation treatment, nearly all of the older men in the study had some problems having sex.
About one-fifth had bladder or bowel trouble, researchers found.
The study doesn’t compare these men – who were 70 to 89 at the end of the study – to others who did not treat their cancers or to older men without the disease. At least one study suggests that half that age group has sexual problems even when healthy.
The study isn’t a rigorous test of surgery and radiation, but it is the longest follow-up of some men who chose those treatments.
Since early prostate cancers usually don’t prove fatal but there are no good ways to tell which ones really need treatment, men must be realistic about side effects they might suffer, said one study leader, Dr. David Penson of Vanderbilt University.
“They need to look at these findings and say, `Oh my gosh, no matter what I choose, I’m going to have some quality-of-life effect and it’s probably greater than my doctor is telling me,’” he said.
Men usually live a long time after treatment – 14 years on average – so it’s important to see how they fare, said another study leader, Vanderbilt’s Dr. Matthew Resnick.
The study involved 1,655 men diagnosed in 1994 or 1995, when they were ages 55 to 74. About two-thirds of them had surgery and the rest, radiation. They were surveyed two, five and 15 years later. By that time, 569 had died.
Men who had surgery had more problems in the first few years after their treatments than those given radiation, but by the end of the study, there was no big difference.
After 15 years, 18 percent of the surgery group and 9 percent of the radiation group reported urinary incontinence, and 5 percent of the surgery group and 16 percent of the radiation group said they were bothered by bowel problems. But the differences between the two groups could have occurred by chance alone once researchers took other factors such as age and the size of the men’s tumors into account.
Impotence was “near universal” at 15 years, the authors write – 94 percent of the radiation group and 87 percent of the surgery group. But the difference between the groups also was considered possibly due to chance. Also, less than half of men said they were bothered by their sexual problems.
“These men do get some help from pills like Viagra, Cialis, Levitra,” but it may not be as much as they would like and most men would rather not need those pills, Penson said. Source.
In conclusion, its good a thing to know the impact of early-stage prostate cancer treatments could have on men. The study used a large number of the male population for its reports.
However, the findings boils down to the fact that prostate cancer side effects may linger on for a very long time after treatment.
The findings of this study have been noted and hopefully it can help men reassess how they can make informed decision about the best treatment option to go for.
A good talk with the doctor can enhance the choice of making an informed treatment decision.